Latest News & Events
Learn more about the latest Delphi Diagnostics news and the Endocrine Activity Index (EAI) Test by reading the press releases below. EAI is known in publications as the Sensitivity to Endocrine Therapy (SET2,3) Test. Clicking on the links below will take you to the full text news pages.
Latest News
New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy
March 5, 2025 – Data from the GEICAM/9906 trial, presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024, provides independent confirmation of the predictive value of the Endocrine Activity Index (EAITM).1 In addition, results from a 12-year outcomes analysis from the CALGB 9741 trial that established EAI as a predictor of benefit from dose-dense chemotherapy in hormone receptor-positive breast cancer was published in the Journal of Clinical Oncology in early January 2025.
All News
August 5, 2024
Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting
April 2, 2023
Delphi Diagnostics® Inc. Announces a Strategic Partnership with Protean BioDiagostics to Offer the Endocrine Activity Index
March 9, 2023
Delphi Diagnostics™ Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX®) in Node-Positive Breast Cancer
October 27, 2022
Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
September 22, 2022
Delphi Diagnostics™ Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
June 13, 2022
SET2,3 Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
December 14, 2021
SET2,3 index adds independent, complementary information to personalize breast cancer treatment
Latest Events
Contact Us
Want to learn more about the Endocrine Activity Index (EAI) or Delphi Diagnostics?